Objectives: The aim of this study was to assess the prevalence of the extended-spectrum b-lactamase (ESBL)-producing enterobacteria (ESBLE) in the French community, during a 2006 survey.
Introduction
Extended-spectrum b-lactamases (ESBLs) are the major cause of resistance to oxyimino-cephalosporins in Enterobacteriaceae. 1 Since the early 2000s, CTX-M-type ESBLs have been increasingly reported and these enzymes have now replaced TEM and SHV as the most common type of ESBL. 2 The CTX-M-blactamase-encoding genes appear to have been captured on transferable plasmids from the chromosome of environmental enterobacteria of the Kluyvera spp. 3 To date, related to genetic polymorphism and/or evolution under selection pressure, more than 80 CTX-M-type b-lactamases have been identified, which are divided into five groups based on their amino acid identities (http://www.lahey.org/Studies). CTX-M enzymes, particularly CTX-M-15, have been involved in various epidemiological situations and have disseminated through all continents, especially in Europe, due to epidemic plasmids and/or particular epidemic strains. 4, 5 A threatening problem is the alarming increase in infections, essentially of the urinary tract, caused by to CTX-M-producing Escherichia coli isolated in non-hospitalized persons. 6 -8 Indeed, these organisms have become widely prevalent in the community setting in some areas of the world, including European countries such as Spain, 7 Italy, 9 Greece 10 and the UK. 11 Recent studies suggest that these strains should not be considered as exclusively nosocomial pathogens but, at least in part, as true community ESBL producers. Furthermore, these bacteria seem to have been imported from the community into the hospital setting. 1 In 1999, we conducted a survey on antibiotic resistance in Enterobacteriaceae collected in general practice in the French Aquitaine region (area IV; Figure 1 ), and ESBL producers were rarely detected in the community setting. 12 -14 However, in recent years, several surveys have indicated that CTX-M b-lactamases were emerging in French hospitals and healthcare institutions such as nursing homes. 15, 16 In addition, some French local studies have reported that patients carried CTX-M-producing strains on their hospital admission. 17 Nevertheless, concurring data for the nation as a whole, and among patients living at home, were lacking. Accordingly, a nationwide survey focusing on ESBL-producing enterobacteria (ESBLE) isolated from urine samples of community patients was performed in 2006, on behalf of the Observatoire National de l'Evolution de la Résistance des Bactéries aux Antibiotiques (ONERBA) (http://www.onerba.org).
The aim of this study was to assess the prevalence of ESBLE in the French community population, to characterize ESBLs and to analyse the epidemiological relationship between ESBL producers.
Materials and methods

Strains and data collection
During a 2 month period (either March -April or April-May 2006), French private laboratories were solicited by ONERBA to collect enterobacteria with a decreased cefotaxime and/or ceftazidime susceptibility (MIC 0.5 mg/L or diameter of the inhibition zone 25 mm) isolated from urinary tract infections (UTIs) of community patients. The corresponding strains were sent to the Microbiologie Cellulaire et Moléculaire et Pathogénicité (MCMP) Laboratory of the Bordeaux 2 University, together with demographic and clinical information on the infected patients. These included: age, gender, co-morbid diseases, hospitalization during the 6 preceding months, administration of antibiotics during the 3 preceding months, contact with healthcare system or professionals (home care, healthcare worker patient or relatives) and known carriage of ESBLE. In order to assess ESBLE prevalence in the community, we recorded the total number of strains isolated from the UTIs of community patients in the same participating laboratories during the study period. In addition, a random sample of patients with ESBL-negative enterobacteria UTIs (947 patients) were asked about prior history of hospitalization. Statistical comparisons were carried out using the x 2 test, with Epi Info software (version 6.04; CDC, USA). A P value ,0.05 was considered statistically significant.
Bacterial strains
The identification of ESBLE to the species level was confirmed by the API20E system (bioMérieux, Marcy-l'É toile, France).
Ambiguous or poorly discriminatory results for seven strains (four Citrobacter koseri, and one strain each of Klebsiella pneumoniae, Klebsiella oxytoca and Citrobacter freundii) were clarified by molecular methods. The molecular identification consisted of PCR amplification and subsequent sequencing of partial fragments of the 16S rDNA and/or of the rpoB gene. 18 Amplification and sequencing of species-specific b-lactamases (bla CKO for C. koseri, bla SHV for K. pneumoniae, bla OXY for K. oxytoca and bla CMY-2 for C. freundii) 19 -21 were also carried out. E. coli strains K12, C600 and TOP10 were used as recipient cells for the transfer experiments by conjugation or transformation. Enterobacteria from the collection of the MCMP Laboratory either producing known b-lactamases or exhibiting previously identified genes (i.e. armA, orf513, ISEcp1 etc.) were added as controls in isoelectrofocusing (IEF) assays and/or PCR amplifications. Plasmid vector pBK-CMV (Stratagene, La Jolla, CA, USA) was used for cloning experiments.
Antimicrobial susceptibility testing b-Lactamase characterization b-Lactamase content of the ESBL-producing strains and their transconjugants were analysed by IEF. 13 The ESBL-encoding genes bla TEM , bla SHV , bla OXA-1 and bla CTX-M were detected by PCR using specific primers 9, 17 and further identified by nucleotide sequence analysis of the PCR products. When several enzymes of the same family co-existed, a separation was carried out by PCR amplification and subsequent cloning. 13 A multiplex PCR protocol was used to detect the presence of plasmid-mediated AmpC b-lactamase genes. 22 
Transfer experiments
Conjugation assays were performed by a filter method using either a nalidixic acid-and rifampicin-resistant (Nal R Rif R ) mutant of E. coli K12, or an azide-resistant (Az R ) mutant of E. coli C600 as recipient strains. 13 Transconjugants were selected on MH agar containing nalidixic acid or rifampicin (100 mg/L) or azide (300 mg/L), plus ampicillin (100 mg/L) or broad-spectrum cephalosporins (ceftazidime, 2 mg/L or cefotaxime, 4 mg/L). When not successful at the first attempt, mating experiments were repeated up to three times.
b-Lactamase gene environment analysis
The genetic environment of the bla CTX-M genes was characterized by PCR amplification with primers annealing to ISEcp1 and to orf513 of ISCR1 together with primers for the bla CTX-M genes. For ISEcp1, two experiments were carried out to amplify the regions located upstream or downstream of the bla CTX-M genes [ pairprimers CTXMA_Rev (5 0 -CTGCACATCGCAAAGCG-3 0 ) with IRR1 (5 0 -GTATTCTGAAGAGTCCAAG-3 0 ) and CTXMB_Rev (5 0 -ACCAACGATATCGCGGT-3 0 ) with IRR2 (5 0 -ACCTGGGACC TACGTGCGCC-3 0 )]. The ISEcp1 element was considered as present if at least one of these two PCR assays was positive. Amplicons for linking ISCR1 with bla CTX-M were obtained by anchoring one primer at the 5 0 end of bla CTX-M (CTXMA_Rev) and the other one to the 3 0 end of orf513 (ORF513FinR, 5 0 -CCGCCACTGACTCCCAGCC-3 0 ). The bla DHA-1 gene from K. oxytoca was cloned in the E. coli TOP10 recipient strain after Sau3AI partial digestion of the conjugative plasmid DNA and ligation in the BamH1-digested pBK-CMV vector. The transformants obtained were selected on a medium containing 2 mg/L ceftazidime.
Analysis of qnr and armA genes
All ESBL-producing strains were screened by PCR amplifications for the presence of qnrA, qnrB and qnrS (quinolone resistance) genes, 23 and the single highly amikacin-resistant strain for armA (aminoglycoside resistance). 24 Amplicons that were obtained were sequenced.
Epidemiological typing
The clonal relationship of the isolates was investigated by PFGE using the CHEF-DRIII system (Bio-Rad) and XbaI-digested (E. coli, Enterobacter aerogenes, C. koseri and K. pneumoniae) or SfiI-digested (Proteus mirabilis) DNA. Profiles were compared using FPQuest TM software (Bio-Rad). For the E. coli strains, the phylogenetic group and subgroup were determined by a multiplex PCR, using a combination of three DNA markers (chuA, yjaA and TspE4.C2). 25, 26 In addition, the presence of the O25b antigen was determined using a PCR-based method. 27 For 10 ESBL-producing E. coli exhibiting the O25b antigen, multilocus sequence typing (MLST) was performed using the primers and methodology indicated on the E. coli MLST web site (http://web.mpiib-berlin.mpg.de/ mlst/dbs/Ecoli).
Results
Clinical data
A total of 25 private laboratories participated in the survey. Their geographic locations were divided into four regions (I -IV), as indicated in Figure 1 . Among 6771 enterobacteria collected from urinary infections by these laboratories during the study period (25 -1000 per laboratory), 151 were found to be resistant to cefotaxime and/or ceftazidime, including 72 non-redundant ESBL-producing strains originating from 20 laboratories. The overall prevalence of ESBLE in UTI in community patients was therefore 1.1% (0% to 3.7% depending on the laboratory). The 72 ESBLE were recovered from 71 patients, most of which exhibited classic risk factors for the acquisition of multidrug-resistant bacteria ( (Table 2) . Finally, when comparing all ESBLE patients with those with non-ESBLE randomly questioned for previous history of hospitalization, the former appeared to have been more frequently hospitalized in the last 6 months than non-ESBLE patients (62.7% versus 17.0%, P, 0.01).
ESBL and additional co-resistance characterization
The 72 ESBL producers are described in Table 2 . They included 48 E. coli (prevalence rate 0.88%, ranging from 0% to 4.7% depending on the laboratory). Among them, 40 expressed a CTX-M enzyme including 23 CTX-M-15. One patient was infected by two ESBLE, i.e. one TEM-24-producing E. aerogenes and the CTX-M-1-producing P. mirabilis. All ESBLE exhibited decreased susceptibilities to cefotaxime and/or ceftazidime that were generally restored by clavulanic acid. They remained susceptible to carbapenems (MIC 90 : ertapenem, 0.05 mg/L; imipenem, 0.1 mg/L) [see Table S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)].
The presence of additional b-lactamases was assessed by a combination of IEF, PCR or cloning experiments when necessary. The results are summarized in Table 2 , and showed the presence of TEM-1-like, OXA-1-like or both enzymes, preferentially among CTX-M producers. Furthermore, all ESBLE with an acquired cefoxitin resistance restored by cloxacillin (increase in the inhibition zone diameter 5 mm) and/or clavulanate -ceftazidime MIC .1 mg/L were subjected to a multiplex PCR for the detection of plasmid-mediated AmpC b-lactamases.
22 Of the 23 strains tested (16 E. coli, 4 C. koseri, 2 K. pneumoniae and 1 K. oxytoca), 2 (1 E. coli CTX-M-15 and 1 K. oxytoca SHV-12) gave a positive amplification for the bla DHA-1 gene.
A total of 86% of the ESBLE were intermediately susceptible or resistant to ofloxacin. However, the detection of the qnrA, qnrB and qnrS genes by PCR amplification led to a single positive result. Indeed, only the SHV-12-producing K. oxytoca strain was found to carry the qnrB4 allele, which co-transferred with bla DHA-1 (discussed subsequently). With regard to aminoglycosides, resistance to gentamicin (29%), amikacin (51%) or both (21%) was associated with a gentamicin -tobramycinnetilmicin, tobramycin-netilmicin -amikacin or gentamicintobramycin -netilmicin -amikacin phenotype, respectively. In addition, one of the CTX-M-15-producing E. coli exhibited high-level resistance to all aminoglycosides due to the armA gene. 24 Resistances to co-trimoxazole (86%), tetracycline (76%) and chloramphenicol (47%) were variable ( Table 2) . Mating assays allowed the transfer of ESBLs from 54 strains (75%), including 30 CTX-M-producing strains, and among them, 19 CTX-M-15. In general, the additional b-lactamase(s) and other previously cited resistances co-transferred with the ESBL (bla TEM-1 -like, 37.5%; bla OXA-1 -like, 61.5%; gentamicin, 78.0%; amikacin, 85.7%; co-trimoxazole, 69.6%; tetracycline, 47.5% and chloramphenicol, 60.9%) (data not shown). Two of the E. aerogenes strains were intermediately susceptible to cefoxitin (MIC, 16 mg/L), due to a non-inducible chromosomal AmpC cephalosporinase, and one strain harboured a low-level tobramycin resistance phenotype probably associated with the low expression of an aac(6 0 )-Ib gene. 16 The four strains of C. koseri exhibited reduced susceptibility or resistance to cefoxitin (MICs, 
Number of strains is indicated in parentheses when .1. The pulsotype is indicated when considered as similar with a similarity percentage .68%. 32 -128 mg/L), probably due to a decrease in an OmpF-like porin, as visualized by the outer membrane protein analysis (data not shown).
Epidemiological typing
The 40 CTX-M-producing E. coli mainly belonged to phylogenetic group A (40%; subgroup A 1 , 94%), followed by the groups B2 (37.5%; B2 3 , 100%), D (20%; D 2 , 87.5%) and B1 (2.5%) ( Table 2) . Among the 23 CTX-M-15-producing E. coli, phylogroup B2 was predominant (57%). Considering a cluster defined at a 68% similarity level, 5 the 13 E. coli of the subgroup B2 divided into four PFGE patterns, including 10 strains assigned to a similar pulsotype C-I. To corroborate the phylogenetic relationship of these 10 strains, MLST and O25b antigen serotyping were performed and showed that they all belonged to the clone ST131-O25b. The other CTX-M-producing E. coli exhibited totally different pulsotypes, including the 3 remaining B2 CTX-M-15-producing E. coli and the 12 A1 E. coli with CTX-M-15 (8 strains) and CTX-M-1 (4 strains). Among the non-CTX-M-producing E. coli, phylogroup A 1 was also predominant (Table 2 ), but no relationship could be found between the strains, except for two of the five TEM-52-producing E. coli ( profile C-II), despite different geographic origins (areas I and III). The nine TEM-24-expressing E. aerogenes displayed a similar genetic background, and their PFGE pattern was similar to that of the E. aerogenes strain harbouring the TEM-46 enzyme (profile C-III). Finally, the other strains analysed by PFGE were distinct, except for the four TEM-3-producing C. koseri, which showed either identical profiles (two strains, region IV) or were closely related (two strains, regions II and IV).
bla CTX-M , bla DHA-1 and qnrB4 genetic environment
The ISEcp1-like and ISCR1 elements were located upstream from 88% (37 strains) and 5% (2 strains bla CTX-M-9 ) of the 42 bla CTX-M genes, respectively. PCR amplification for ISEcp1-like and ISCR1 was negative for three strains (two bla CTX-M-14 and one bla CTX-M-27 ). The SHV-12-producing K. oxytoca strain, which belonged to the phylogenetic group KoI (bla OXY-5-2 gene), 21 contained the qnrB4 and bla DHA-1 genes 4.1 kb apart in the vicinity of phage shock protein genes, on the 8.161 kb plasmid fragment analysed [ Figure S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)].
Discussion
This first nationwide survey on ESBLE in the French community setting showed an overall prevalence rate of 1.1% from UTIs in 2006. Such prevalence is only slightly lower than that reported in 2005 for 88 French hospitals (1.5%). 15 It is similar to those recorded in the community of a neighbouring country (Spain, 1.4% to 1.7%).
7,28 When comparing the 0.3% proportion observed in a regional survey (area IV) in 1999, our findings of 1.4% in the same region in the present survey suggest a significant increase in ESBLE in the French community. 12, 13 Such an increase in ESBLE could be ascribed to the expansion of CTX-M-producing E. coli ( prevalence rate, 0.73% in 2006 versus 0% in our regional survey in 1999) in France as in other European countries. 7,9 -11 Indeed, two-thirds of the ESBLE recovered in the present study were E. coli and most of them (83%) expressed CTX-M enzymes. However, the CTX-Mproducing E. coli formed a very heterogeneous population: part of the strains belonged to the less-virulent commensal phylogenetic groups A and B1, while others belonged to the virulent extra-intestinal phylogenetic groups B2 and D, 26, 29 and thus expressed seven varieties of CTX-M enzymes. Nevertheless, among the 23 E. coli of subgroup B2 3 , more than half were CTX-M-15-producers. Using a fine resolution tool (PFGE clustering analysis classically defined by a percent similarity exceeding 85%), only four of them appeared to be clonal. However, based on a lower percent similarity, 5 six other strains could be considered as related. Furthermore, MLST and serotyping analysis showed that all 10 strains belonged to the ST131-O25b clone disseminated worldwide, 4, 5, 29 as in the community of all French regions. These results are consistent with a CTX-M dissemination associated with different E. coli lineages, and the occasional emergence of particularly well-adapted strains, such as the ST131-O25b clone. 26 In our study, two non-E. coli strains, K. pneumoniae and P. mirabilis, also expressed a group 1 CTX-M enzyme. Such strains might once supplant CTX-M-producing E. coli, at least in the hospital environment, as illustrated by the recent dissemination of nosocomial CTX-M-15-producing K. pneumoniae in Hungary, representing 97% of all CTX-M producers. 30 Following CTX-M-15, CTX-M-1 and CTX-M-14 were the most frequent enzymes as in nearby countries, Italy and Spain.
1 A great variety of CTX-M enzymes has been identified in French hospitals, including the remaining CTX-M-2, CTX-M-3, CTX-M-9 and CTX-M-27 ESBLs characterized here. 1, 2 CTX-M-27 only differs from the more common CTX-M-14 by the substitution D240G, which confers the advantage of higher levels of ceftazidime resistance, as in CTX-M-15. 31 The explosive dissemination of different CTX-M enzymes has been related to the fact that the genes encoding these enzymes are associated with highly transmissible mobile genetic elements. 1 In particular, ISEcp1 has been shown to transfer bla CTX-M genes from the bacterial chromosome of Kluyvera spp. to conjugative plasmids. 1 In agreement with the literature, most of the bla CTX-M genes of our study were linked to an ISEcp1-like element, except the two bla CTX-M-9 genes that were embedded in a complex class 1 integron bearing ISCR1. The presence of phage-related elements or insertion/deletion events within ISEcp1 might explain the negative PCR results for three group 9 bla CTX-M genes. 4 Our case -control study confirmed that a recent hospitalization (or residence in private healthcare institutions) is a major risk factor for developing community-onset ESBL-producing bacterial infections. 28, 32, 33 Up to 80% of the patients received a recent antibiotic treatment, confirming that the previous use of fluoroquinolones and b-lactams was a risk factor for selection of ESBLE. 7, 28, 33 However, it is noteworthy that except for antimicrobial therapy, all risk factors documented in our study for acquiring ESBLE were less frequent when the ESBL belonged to the CTX-M family, especially advanced age and home care (P,0.05). In particular, 13 patients (18.3%) were considered as infected by a true community-acquired ESBLE. In 12 of them, the ESBLE was a CTX-M-producing E. coli, including 5 belonging to phylogroup B2 3 and the remaining ones divided into groups A1 or D2. They carried various CTX-M enzymes, and only one of them belonged to the ST131-O25b clone. Ben-Ami et al.
33 also reported that nearly 20% of the patients infected with ESBLE at the time of hospital admission had no identifiable risk factors. Altogether, these data reinforce the hypothesis that the CTX-M enzymes have a reservoir other than the hospital. 1 In addition, CTX-M-producing E. coli have been encountered in sick or healthy animals, and in their meat products. 34 These potential ESBL sources or reservoirs probably increase the dispersal of resistance in healthy people. 34 The non-CTX-M-producing strains, including eight E. coli, essentially produced TEM-type ESBLs (93%, seven varieties of enzymes) and rarely SHV-type ESBLs (7%, 1 SHV-12). Among them, the TEM-24 or TEM-46 positive E. aerogenes belonged to the epidemic clone prevalent in French hospitals at the end of the 1990s. 13 Interestingly, TEM-46 differs from TEM-24 by the single amino acid substitution A237T that confers lower hydrolytic capabilities. 35 Although there is a progressive decline of this clone in the hospital setting, 15 it always represents a stable fraction of the Enterobacter spp. in the community (ca. 4%), but tends to a higher and unusual antibiotic susceptibility. 13 These isolates have been found in community patients with a past history of repeated hospitalizations due to a prolonged digestive carriage.
14 Four TEM-3-producing C. koseri have been identified that exhibited a cefoxitin resistance usually characteristic of C. freundii. This resistance could be ascribed to the reduced production of an OmpF-like porin. TEM-3-producing E. coli (as one example here) has been among the first ESBLE responsible for nosocomial outbreaks in the 1980s. 36 Later, French nosocomial outbreaks caused by TEM-3-producing C. koseri have been reported. 37, 38 Cefoxitin-resistant mutants may have emerged once under therapy and have persisted in patients discharged from hospital as TEM-24-producing E. aerogenes.
14 TEM-24, TEM-46 and TEM-21 were encoded by highly conjugative plasmids, explaining their in vivo transfer to a variety of enterobacterial species. 16 Finally, other TEM-and SHV-producing strains found in our study included TEM-15, TEM-29, TEM-52 and SHV-12 producers. These strains, mainly those associated with TEM-52, have been described in hospitals in France 16, 39 and in bordering countries such as Italy. 40 We have also previously detected a TEM-15 enzyme in K. pneumoniae in the French community.
14 In addition, TEM-52 and SHV-12 producers have been described in animals and in river waters, indicating that all ESBLs, and not exclusively CTX-M enzymes, are now largely disseminated out of hospitals. 34, 41 Most of the ESBLE were resistant to the other classes of antibiotics, in particular fluoroquinolones and/or co-trimoxazole, which are commonly prescribed by general practitioners, especially for UTIs. Furthermore, our study has revealed the presence of plasmid-mediated broad-spectrum resistances co-existing with ESBLs, such as the plasmid-mediated cephalosporinase DHA-1 in one CTX-M-15-producing E. coli, and in the SHV-12-producing K. oxytoca. Another CTX-M-15 E. coli harboured the gene armA encoding 16S rRNA methylase which confers pan-aminoglycoside resistance. Although most of the ESBLE were resistant to fluoroquinolones, a single strain carried a qnr determinant, the qnrB4 allele. However, other plasmidmediated resistances such as aac(6 0 )-Ib-cr genes have been reported to confer quinolone resistances. 42 DHA-1, ArmA and QnrB are widespread in Asia, but are rarely encountered in Europe, particularly in France, among nosocomial isolates or occasionally in animal strains. 43, 44 This is the first description in the community setting for ArmA worldwide and for DHA-1 and QnrB4 in France. Indeed, one E. coli strain harbouring qnrB4 and bla DHA-1 and six Italian E. coli carrying a qnrB-like gene have just been reported in the community setting in Switzerland and Italy, respectively. 45, 46 In the K. oxytoca strain of this study, transfer experiments showed that the qnr and bla DHA-1 genes were linked, while bla SHV-12 was carried by another conjugative plasmid. Sequence analysis demonstrated that the fragment encompassing qnrB4 and bla DHA-1 was identical to that found in plasmid pHS7 of K. pneumoniae isolated in China 47 and, although unmentioned by the authors, in plasmid pPMDHA of one Parisian strain of K. oxytoca. 43 In the future, it will be interesting to include recent foreign travel as a risk factor for acquiring multidrug-resistant bacteria.
32
In conclusion, this survey has highlighted a significant increase in ESBLE in the French community setting, up to 1.1% of the urinary enterobacteria. Analysis of these ESBLE has revealed a great diversity of bacterial species and enzymes. Nevertheless, most were CTX-M-producing E. coli, including a cluster of the pandemic CTX-M-15-expressing clone ST131-O25b. Furthermore, clones harbouring determinants that confer still unusual resistances such as DHA-1, ArmA or QnrB4 were present in these community strains. This worrisome development implies enhanced capabilities for the detection of resistance mechanisms by private as well as public laboratories, in order to implement appropriate infection control practices, and to prescribe adapted chemotherapeutic agents.
